Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dose-regimen study of INCB018424 in hydroxyurea-refractory polycythemia vera or essential thrombocythemia
2008-001382-28Phase 2Completed
- Sponsor
- Incyte
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib in polycythemia vera (PV) and thrombocythemia (2 cohorts), sponsored by Incyte. Primary endpoints: Complete response rate, Partial response rate and 2 more. Started Oct 2008; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)thrombocythemia
Beyond the preview
Go deeper on 2008-001382-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001382-28.